Literature DB >> 9174606

The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9.

V Braud1, E Y Jones, A McMichael.   

Abstract

Human histocompatibility leukocyte antigen E (HLA-E) and mouse major histocompatibility complex (MHC) class Ib antigen, Qa-1, share the same substitutions at two normally conserved positions 143 and 147, which are likely to affect binding of the C terminus of peptides. Qa-1 is able to bind a peptide derived from the leader sequence of H-2 D and H-2 L molecules. We developed a peptide binding assay in vitro to compare the binding specificity of HLA-E with the mouse MHC class Ib molecule Qa-1. We demonstrate that HLA-E binds, although poorly, the peptide which binds to Qa-1 and that it also binds nonamer signal sequence-derived peptides from human MHC class I molecules. Using alanine and glycine substitutions, we could define primary anchor residues at positions 2 and 9 and secondary anchor residues at position 7 and possibly 3.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9174606     DOI: 10.1002/eji.1830270517

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  130 in total

1.  Pivotal role of CEACAM1 protein in the inhibition of activated decidual lymphocyte functions.

Authors:  Gal Markel; Dana Wolf; Jacob Hanna; Roi Gazit; Debra Goldman-Wohl; Yuval Lavy; Simcha Yagel; Ofer Mandelboim
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

2.  The DY genes of the cattle MHC: expression and comparative analysis of an unusual class II MHC gene pair.

Authors:  Keith T Ballingall; Shirley A Ellis; Niall D MacHugh; Stephen D Archibald; Declan J McKeever
Journal:  Immunogenetics       Date:  2004-01-24       Impact factor: 2.846

3.  HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes.

Authors:  Gabriella Pietra; Chiara Romagnani; Paola Mazzarino; Michela Falco; Enrico Millo; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

Review 4.  Qa-1, a nonclassical class I histocompatibility molecule with roles in innate and adaptive immunity.

Authors:  Peter E Jensen; Barbara A Sullivan; Lisa M Reed-Loisel; Dominique A Weber
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 5.  Regulation of self-tolerance by Qa-1-restricted CD8(+) regulatory T cells.

Authors:  Hye-Jung Kim; Harvey Cantor
Journal:  Semin Immunol       Date:  2011-12       Impact factor: 11.130

6.  Natural killer cells fertile with receptors for HLA-G?

Authors:  L L Lanier
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

7.  Human Leukocyte Antigen F Presents Peptides and Regulates Immunity through Interactions with NK Cell Receptors.

Authors:  Charles L Dulberger; Curtis P McMurtrey; Angelique Hölzemer; Karlynn E Neu; Victor Liu; Adriana M Steinbach; Wilfredo F Garcia-Beltran; Michael Sulak; Bana Jabri; Vincent J Lynch; Marcus Altfeld; William H Hildebrand; Erin J Adams
Journal:  Immunity       Date:  2017-06-20       Impact factor: 31.745

Review 8.  Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules.

Authors:  Peter Parham; Paul J Norman; Laurent Abi-Rached; Lisbeth A Guethlein
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-03-19       Impact factor: 6.237

9.  Molecular cloning, expression, and immunogenicity of MTB12, a novel low-molecular-weight antigen secreted by Mycobacterium tuberculosis.

Authors:  J R Webb; T S Vedvick; M R Alderson; J A Guderian; S S Jen; P J Ovendale; S M Johnson; S G Reed; Y A Skeiky
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 10.  Natural killer cell receptors and their ligands in liver diseases.

Authors:  Satoshi Yamagiwa; Hiroteru Kamimura; Takafumi Ichida
Journal:  Med Mol Morphol       Date:  2009-03-18       Impact factor: 2.309

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.